Genmab reported topline Phase 3 results from Epcore DLBCL-1 showing that subcutaneous epcoritamab monotherapy improved progression-free survival versus investigator’s choice of R-GemOx or BR in transplant-ineligible patients with relapsed or refractory diffuse large B‑cell lymphoma. The hazard ratio for PFS was 0.74, with higher complete response rates, longer duration of response, and longer time to next treatment favoring epcoritamab. Overall survival did not reach statistical significance (HR 0.96). The 483‑patient, global, open‑label study enrolled a population largely treated with two or more prior lines, and safety appeared consistent with the known profile. Genmab and AbbVie plan to engage regulators, with full data to follow at an upcoming meeting, and readouts from two fixed‑duration Phase 3 programs expected in 2026.
The strategic question is whether a clear PFS win—without an OS signal—can move the needle on standard-of-care and reimbursement in a crowded, fast-evolving lymphoma market. For a transplant‑ineligible population often excluded from CAR‑T, preventing progression and deferring next therapy are clinically meaningful, especially with a subcutaneous regimen that can be delivered in community settings. Yet payers and health technology bodies have grown more exacting, frequently demanding OS or robust quality‑of‑life and resource‑utilization gains to justify premium pricing for continuous T‑cell–redirecting therapies.
This matters now because the second‑line and later DLBCL landscape is fragmenting into distinct pathways: fixed‑course IV bispecifics, chronic subcutaneous bispecifics, and one‑time cellular therapies. Epcoritamab is already approved in more than 65 countries in certain lymphoma settings and has differentiated on convenience with subcutaneous administration. However, duration of therapy is an emerging battleground. Roche’s glofitamab established a fixed‑duration template in DLBCL, and Genmab/AbbVie are racing to validate fixed‑duration epcoritamab regimens in frontline and relapsed settings. If the upcoming fixed‑duration trials read out positively, they could blunt payer concerns around long treatment tails and budget impact while improving patient acceptability and clinic throughput.
For Commercial leaders, positioning will hinge on two variables: sequencing relative to CAR‑T and head‑to‑head or cross‑trial differentiation against other CD3×CD20 bispecifics. Many transplant‑ineligible patients will never reach CAR‑T due to age, comorbidities, logistics, or capacity constraints. Demonstrating that epcoritamab reliably keeps these patients off cytotoxic salvage therapy and out of the hospital could resonate with payers, particularly if accompanied by real‑world data on reduced admissions for cytokine release syndrome and streamlined outpatient management. Conversely, continuous dosing against chemotherapy comparators may invite tough cost‑effectiveness scrutiny in markets where CAR‑T is reimbursed earlier and fixed‑course bispecifics are available.
Medical Affairs teams should prepare to generate and communicate evidence beyond PFS: patient‑reported outcomes, time in remission without steroids, emergency visits, and caregiver burden will be pivotal in HTA dossiers. Education on CRS and neurotoxicity mitigation in community oncology settings remains essential to broaden adoption, as does guidance on sequencing after or before CAR‑T and bridging strategies. As epcoritamab moves into combinations, particularly with R‑CHOP in frontline disease, clear narratives on patient selection and toxicity trade‑offs will be needed to reassure hematologists and payers.
The broader trend is unmistakable: bispecifics are advancing from late‑line salvage to earlier, potentially curative-intent settings, challenging the CAR‑T “one‑and‑done” paradigm with more scalable, outpatient‑friendly options. The next inflection point will be whether fixed‑duration epcoritamab can match its PFS advantage with a value proposition that satisfies HTAs and compels guideline elevation. If not, will the market settle into a bifurcated model—fixed‑course bispecifics for cost-contained settings and continuous subcutaneous regimens for access‑constrained segments—or can one approach become dominant as evidence matures?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
